Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model
- PMID: 20331379
- DOI: 10.1086/651558
Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model
Abstract
Candida species are a major cause of catheter infections. Using a central venous catheter Candida albicans biofilm model, we demonstrated that chitosan, a polymer isolated from crustacean exoskeletons, inhibits candidal biofilm formation in vivo. Furthermore, chitosan statistically significantly decreased both the metabolic activity of the biofilms and the cell viability of C. albicans and Candida parapsilosis biofilms in vitro. In addition, confocal and scanning electron microscopic examination demonstrated that chitosan penetrates candidal biofilms and damages fungal cells. Importantly, the concentrations of chitosan that were used to evaluate fungal biofilm susceptibility were not toxic to human endothelial cells. Chitosan should be considered for the prevention or treatment of fungal biofilms on central venous catheters and perhaps other medical devices.
Similar articles
-
Sustained Nitric Oxide-Releasing Nanoparticles Induce Cell Death in Candida albicans Yeast and Hyphal Cells, Preventing Biofilm Formation In Vitro and in a Rodent Central Venous Catheter Model.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2185-94. doi: 10.1128/AAC.02659-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26810653 Free PMC article.
-
In vivo antibiofilm effect of cerium, chitosan and hamamelitannin against usual agents of catheter-related bloodstream infections.J Antimicrob Chemother. 2013 Jan;68(1):126-30. doi: 10.1093/jac/dks376. Epub 2012 Sep 18. J Antimicrob Chemother. 2013. PMID: 22991425
-
Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis.J Antimicrob Chemother. 2009 Sep;64(3):567-70. doi: 10.1093/jac/dkp242. Epub 2009 Jul 7. J Antimicrob Chemother. 2009. PMID: 19584104
-
Antifungal lock therapy.Antimicrob Agents Chemother. 2013 Jan;57(1):1-8. doi: 10.1128/AAC.masthead.57-1. Epub 2012 Oct 15. Antimicrob Agents Chemother. 2013. PMID: 23070153 Free PMC article. Review.
-
Antifungal susceptibility of Candida albicans in biofilms.Mycoses. 2012 May;55(3):199-204. doi: 10.1111/j.1439-0507.2011.02076.x. Epub 2011 Jul 28. Mycoses. 2012. PMID: 21793943 Review.
Cited by
-
Cranberry proanthocyanidins inhibit the adherence properties of Candida albicans and cytokine secretion by oral epithelial cells.BMC Complement Altern Med. 2012 Jan 16;12:6. doi: 10.1186/1472-6882-12-6. BMC Complement Altern Med. 2012. PMID: 22248145 Free PMC article.
-
In vivo effect of quaternized chitosan-loaded polymethylmethacrylate bone cement on methicillin-resistant Staphylococcus epidermidis infection of the tibial metaphysis in a rabbit model.Antimicrob Agents Chemother. 2014 Oct;58(10):6016-23. doi: 10.1128/AAC.03489-14. Epub 2014 Jul 28. Antimicrob Agents Chemother. 2014. PMID: 25070107 Free PMC article.
-
Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts.PLoS One. 2019 Dec 31;14(12):e0227098. doi: 10.1371/journal.pone.0227098. eCollection 2019. PLoS One. 2019. PMID: 31891619 Free PMC article.
-
Synergistic Antifungal Activity of Chito-Oligosaccharides and Commercial Antifungals on Biofilms of Clinical Candida Isolates.J Fungi (Basel). 2021 Sep 1;7(9):718. doi: 10.3390/jof7090718. J Fungi (Basel). 2021. PMID: 34575756 Free PMC article.
-
Chitosan-Based Nanomedicine to Fight Genital Candida Infections: Chitosomes.Mar Drugs. 2017 Mar 4;15(3):64. doi: 10.3390/md15030064. Mar Drugs. 2017. PMID: 28273850 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical